Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update May 11, 2023
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development May 4, 2023
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison May 3, 2023
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform Apr 11, 2023
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update Mar 23, 2023
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event Mar 16, 2023
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy Jan 17, 2023
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event Jan 5, 2023
